Drug Profile
ABISCAN
Latest Information Update: 22 Dec 2003
Price :
$50
*
At a glance
- Originator Molecular Targeting Technologies
- Class Radiopharmaceutical diagnostics; Sugar acids
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 22 Dec 2003 Discontinued - Phase-I for Stroke (diagnosis) in USA (unspecified route)
- 05 Nov 2003 Phase-I clinical trials in Stroke (diagnosis) in USA (unspecified route)
- 13 Nov 2001 Preclinical development for Stroke (diagnosis) in USA (unspecified route)